Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,209.01
(
1.02%
)
US TECH 100
26,736.40
(
1.03%
)
Dow Jones
49,652.14
(
1.62%
)
Brent Oil
111.06
(
0.64%
)
Bitcoin
77,125.99
(
1.04%
)
News Focus
News Focus
Post# of 257473
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122916
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 135738

Wednesday, 05/29/2013 4:41:10 PM

Wednesday, May 29, 2013 4:41:10 PM

Post# of 257473
AMGN, Astellas ink drug-development/commercialization JV for Japanese market:

http://finance.yahoo.com/news/amgen-astellas-announce-japan-alliance-041200972.html

The JV’s pipeline will consist of the following five AMGN drugs:

• AMG 145 (PCSK9 inhibitor) for CV disease, in phase-3 (phase-2 in Japan)

• AMG 785/Romosozumab for osteoporosis in phase-3

• AMG 102/Rilotumumab for GI cancer in phase-3 (phase-1 in Japan)

• AMG 337 (MET inhibitor) for GI cancer in phase-1

• AMG 103/Blinatumomab (acquired from MITI) for ALL/NHL in phase-2

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today